Dermata Therapeutics (NASDAQ:DRMA) vs. Nu Skin Enterprises (NYSE:NUS) Head-To-Head Review

Dermata Therapeutics (NASDAQ:DRMA) and Nu Skin Enterprises (NYSE:NUS) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Insider & Institutional Ownership

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 2.8% of Nu Skin Enterprises shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Dermata Therapeutics and Nu Skin Enterprises”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56 million	($4.39)	-0.31
Nu Skin Enterprises	$1.49 billion	0.16	$160.20 million	($4.47)	-1.09

Nu Skin Enterprises has higher revenue and earnings than Dermata Therapeutics. Nu Skin Enterprises is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Dermata Therapeutics and Nu Skin Enterprises, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1	0	0	0	1.00
Nu Skin Enterprises	2	0	0	0	1.00

Profitability

This table compares Dermata Therapeutics and Nu Skin Enterprises’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-166.66%	-130.13%
Nu Skin Enterprises	-15.73%	6.58%	3.63%

Volatility & Risk

Dermata Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Nu Skin Enterprises has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Summary

Nu Skin Enterprises beats Dermata Therapeutics on 6 of the 10 factors compared between the two stocks.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.